Skip to main content
. 2017 May 11;14(6):2147–2157. doi: 10.1021/acs.molpharmaceut.7b00308

Figure 4.

Figure 4

Cetuximab reduced methotrexate-induced cytotoxicity in ciPTEC-OAT1. Exposure to cetuximab (CTX) for 24 h reduced the uptake of methotrexate (MTX) in both CM (A) and SFM (B). CTX pretreatment effectively rests cell cycle progression (C). For cell viability assessments, cells were exposed to methotrexate (0–100 μM) for 24 h in SFM (D), MTX (100 μM) for 24 h in SFM, followed by 24 h of treatment with CM (E) or CTX. Cells were preconditioned for 24 h in SFM with CTX or U-0126 (2 μM), followed by 48 h of exposure to MTX (100 μM) (F). MTT assay was then performed. CTX preconditioning did not rescue MTX cytotoxicity in ciPTEC-OAT3 (G). Results are expressed in viability (%) compared to control (i.e., SFM-treated cells). CTX pretreatment effectively reduced MTX uptake and toxicity. Values are shown as mean ± SEM of minimally two independent experiments performed in triplicates. ∗, Significantly different from control (p < 0.05); #, significantly different from MTX (100 μM; p < 0.05).